United TherapeuticsUTHR
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$23.3B
Price
$546.63
Today
−1.1%
Return YTD
+13.4%
Return 1Y
+83.8%
P/E
18.1
P/S
7.4
P/B
4.0
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- PAH treatments (Tyvaso)
- Remodulin & Orenitram
- Organ & transplant technology
Competitors
- Johnson & Johnson
- Merck
- Liquidia
Risks
- PAH competition
- Pipeline execution
Same segment: Biotech & innovation
See where United Therapeutics sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →